Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis

被引：27

作者：

Shima, Yoshihito ^{[1
]}

Tomita, Tetsuya ^{[2
]}

Ishii, Taeko ^{[1
]}

Morishima, Atsuyoshi ^{[1
]}

Maeda, Yuichi ^{[3
]}

Ogata, Atsushi ^{[1
]}

Kishimoto, Tadamitsu ^{[4
]}

Tanaka, Toshio ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Dept Orthopaed, Suita, Osaka 5650871, Japan

[3] Natl Hosp Org, Osaka Minami Med Ctr, Dept Rheumatol, Osaka, Japan

[4] Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Suita, Osaka 5650871, Japan

来源：

MODERN RHEUMATOLOGY | 2011年 / 21卷 / 04期

关键词：

Ankylosing spondylitis; IL-6; Tocilizumab; DISEASE-ACTIVITY; CONTROLLED-TRIAL; INDEX; BATH; INTERLEUKIN-6; ETANERCEPT; INFLIXIMAB; ARTHRITIS; THERAPY; IL-6;

D O I：

10.1007/s10165-011-0416-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS.

引用

页码：436 / 439

页数：4

共 19 条

[1] Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
Brandt, J
Khariouzov, A
Listing, J
Haibel, H
Sörensen, H
Grassnickel, L
Rudwaleit, M
Sieper, J
Braun, J
[J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (06): : 1667 - 1675
[2] Ankylosing spondylitis
Braun, Juergen
Sieper, Joachim
[J]. LANCET, 2007, 369 (9570) : 1379 - 1390
[3] Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists
Brulhart, Laure
Nissen, Michael J.
Chevallier, Paola
Gabay, Cem
[J]. JOINT BONE SPINE, 2010, 77 (06) : 625 - 626
[4] CALIN A, 1994, J RHEUMATOL, V21, P2281
[5] Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial
Davis, JC
van der Heijde, D
Braun, J
Dougados, M
Cush, J
Clegg, DO
Kivitz, A
Fleischmann, R
Inman, R
Tsuji, W
[J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3230 - 3236
[6] Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year?
Falkenbach, A
Herold, M
Wigand, R
[J]. RHEUMATOLOGY INTERNATIONAL, 2000, 19 (04) : 149 - 151
[7] GARRETT S, 1994, J RHEUMATOL, V21, P2286
[8] GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927
[9] Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week openlabel trial
Haibel, H
Rudwaleit, M
Brandt, HC
Grozdanovic, Z
Listing, J
Kupper, H
Braun, J
Sieper, J
[J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (02): : 678 - 681
[10] Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis
Hayer, Silvia
Niederreiter, Birgit
Nagelreiter, Ionela
Smolen, Josef
Redlich, Kurt
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (07) : 1403 - 1406

← 1 2 →